These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 9849693

  • 1. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H, Perry G, Genest P, Huebsch L.
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [Abstract] [Full Text] [Related]

  • 2. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH, Schulman KA, Buckner CD.
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [Abstract] [Full Text] [Related]

  • 3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 4. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
    Benet I, Prosper BF, Marugan I, Lluch A, Arbona C, Castillo I, Solano C, Garcia-Conde J.
    Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
    [Abstract] [Full Text] [Related]

  • 5. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A.
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [Abstract] [Full Text] [Related]

  • 6. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
    Spitzer G, Adkins D, Mathews M, Velasquez W, Bowers C, Dunphy F, Kronmueller N, Niemeyer R, McIntyre W, Petruska P.
    Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
    [Abstract] [Full Text] [Related]

  • 7. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L, Masia CM, Centurioni R, Mancini S, Brunori M, Leoni P.
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [Abstract] [Full Text] [Related]

  • 8. Delayed administration of G-CSF until day +7 after autologous peripheral blood stem cell transplant is as effective in accelerating hematopoietic as day 0.
    Sobrevilla-Calvo P, Zinser Sierra JW, Lara Medina FU, Acosta Barreda A, Calderón Flores E.
    Rev Invest Clin; 2002 Apr; 54(1):51-6. PubMed ID: 11995407
    [Abstract] [Full Text] [Related]

  • 9. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD.
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [Abstract] [Full Text] [Related]

  • 10. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
    Ossenkoppele GJ, Jonkhoff AR, Huijgens PC, Nauta JJ, van der Hem KG, Dräger AM, Langenhuijsen MM.
    Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
    [Abstract] [Full Text] [Related]

  • 11. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
    Alegre A, Tomás JF, Martínez-Chamorro C, Gil-Fernández JJ, Fernández-Villalta MJ, Arranz R, Díaz MA, Granda A, Bernardo MR, Escudero A, López-Lorenzo JL, Fernández-Rañada JM.
    Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
    [Abstract] [Full Text] [Related]

  • 12. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation.
    Cetkovský P, Koza V, Jindra P, Skopek P, Svojgrová M.
    Bone Marrow Transplant; 1997 Oct; 20(8):639-41. PubMed ID: 9383226
    [Abstract] [Full Text] [Related]

  • 13. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S, Arpaci F, Turan M, Solchaga L, Cetin T, Ozturk M, Ozet A, Komurcu S, Ozturk B.
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [Abstract] [Full Text] [Related]

  • 14. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G, Patoia L, Giglietti A, Alessio M, Pelicci P, Grignani F.
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [Abstract] [Full Text] [Related]

  • 15. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation.
    de Azevedo AM, Nucci M, Maiolino A, Vigorito AC, Simões BP, Aranha FJ, Tabak DG, Voltarelli J, de Souza CA.
    Bone Marrow Transplant; 2002 May; 29(9):745-51. PubMed ID: 12040471
    [Abstract] [Full Text] [Related]

  • 16. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
    Greenberg P, Advani R, Keating A, Gulati SC, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K, Cuffie C.
    Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
    [Abstract] [Full Text] [Related]

  • 17. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs.
    Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M, Novarino A, Tassi V, Pileri A.
    Bone Marrow Transplant; 1998 Feb; 21(4):401-7. PubMed ID: 9509976
    [Abstract] [Full Text] [Related]

  • 18. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.
    Faucher C, Le Corroller AG, Chabannon C, Novakovitch G, Manonni P, Moatti JP, Nouyrigat P, Maraninchi D, Blaise D.
    Bone Marrow Transplant; 1996 Apr; 17(4):533-6. PubMed ID: 8722350
    [Abstract] [Full Text] [Related]

  • 19. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Färber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R.
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [Abstract] [Full Text] [Related]

  • 20. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
    Ozcan M, Ustün C, Akçağlayan E, Akan H, Arslan O, Ilhan O, Beksaç M, Gürman G, Demirer T, Arat M, Celebi H, Konuk N, Uysal A, Koç H.
    Bone Marrow Transplant; 2001 Mar; 27(5):499-505. PubMed ID: 11313683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.